Abstract
Despite the efficacy of most cancer therapies, drug resistance remains a major problem in the clinic. The eradication of the entire tumor and the cure of the patient by chemotherapy alone are rare, in particular for advanced disease. From an evolutionary perspective, the selective pressure exerted by chemotherapy leads to the emergence of resistant clones where resistance can be associated with many different functional mechanisms at the single cell level or can involve changes in the tumor micro-environment. In the last decade, tumor genomics has contributed to the improvement of our understanding of tumorigenesis and has led to the identification of numerous cellular targets for the development of novel therapies. However, since tumors are by nature extremely heterogeneous, the drug efficacy and economical sustainability of this approach is now debatable. Importantly, tumor cell heterogeneity depends not only on genetic modifications but also on non-genetic processes involving either stochastic events or epigenetic modifications making genetic biomarkers of uncertain utility. In this review, we wish to highlight how evolutionary biology can impact our understanding of carcinogenesis and resistance to therapies. We will discuss new approaches based on applied ecology and evolution dynamics that can be used to convert the cancer into a chronic disease where the drugs would control tumor growth. Finally, we will discuss the way metabolic dysfunction or phenotypic changes can help developing new delivery systems or phenotypetargeted drugs and how exploring new sources of active compounds can conduct to the development of drugs with original mechanisms of action.
Keywords: Cancer heterogeneity, selective pressure, cancer chemotherapeutics, biomarkers, drug resistance, phenotypic drug screening, natural products, economics.
Current Pharmaceutical Design
Title:Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology
Volume: 22 Issue: 44
Author(s): Alexandre E. Escargueil, Soizic Prado, Ambre Dezaire, Jean Clairambault, Annette K. Larsen and Daniele G. Soares
Affiliation:
Keywords: Cancer heterogeneity, selective pressure, cancer chemotherapeutics, biomarkers, drug resistance, phenotypic drug screening, natural products, economics.
Abstract: Despite the efficacy of most cancer therapies, drug resistance remains a major problem in the clinic. The eradication of the entire tumor and the cure of the patient by chemotherapy alone are rare, in particular for advanced disease. From an evolutionary perspective, the selective pressure exerted by chemotherapy leads to the emergence of resistant clones where resistance can be associated with many different functional mechanisms at the single cell level or can involve changes in the tumor micro-environment. In the last decade, tumor genomics has contributed to the improvement of our understanding of tumorigenesis and has led to the identification of numerous cellular targets for the development of novel therapies. However, since tumors are by nature extremely heterogeneous, the drug efficacy and economical sustainability of this approach is now debatable. Importantly, tumor cell heterogeneity depends not only on genetic modifications but also on non-genetic processes involving either stochastic events or epigenetic modifications making genetic biomarkers of uncertain utility. In this review, we wish to highlight how evolutionary biology can impact our understanding of carcinogenesis and resistance to therapies. We will discuss new approaches based on applied ecology and evolution dynamics that can be used to convert the cancer into a chronic disease where the drugs would control tumor growth. Finally, we will discuss the way metabolic dysfunction or phenotypic changes can help developing new delivery systems or phenotypetargeted drugs and how exploring new sources of active compounds can conduct to the development of drugs with original mechanisms of action.
Export Options
About this article
Cite this article as:
Escargueil E. Alexandre, Prado Soizic, Dezaire Ambre, Clairambault Jean, Larsen K. Annette and Soares G. Daniele, Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology, Current Pharmaceutical Design 2016; 22 (44) . https://dx.doi.org/10.2174/1381612822666160831114002
DOI https://dx.doi.org/10.2174/1381612822666160831114002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews An efficient Synthesis of New Fused Oxazinocarbazoles
Letters in Organic Chemistry New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy A Review on Anti-urease Potential of Coumarins
Current Drug Targets Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Gist Representations and Communication of Risks about HIV-AIDS: A Fuzzy-Trace Theory Approach
Current HIV Research Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design Oncostatin M: Potential Implications for Malignancy and Metabolism
Current Pharmaceutical Design Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy Iodine in Mammary and Prostate Pathologies
Current Chemical Biology Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis From the Sea to Anticancer Therapy
Current Medicinal Chemistry Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research